Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.

<h4>Aim</h4>The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.<h4>Methods</h4>All observational studies and randomized contro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xulei Tang, Lin Yang, Zhiyu He, Jingfang Liu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/13714cf8c35a4c73948ef31ba6116386
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:13714cf8c35a4c73948ef31ba6116386
record_format	dspace
spelling	oai:doaj.org-article:13714cf8c35a4c73948ef31ba61163862021-11-18T08:04:32ZInsulin glargine and cancer risk in patients with diabetes: a meta-analysis.1932-620310.1371/journal.pone.0051814https://doaj.org/article/13714cf8c35a4c73948ef31ba61163862012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23284776/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aim</h4>The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.<h4>Methods</h4>All observational studies and randomized controlled trials evaluating the relationship of insulin glargine and cancer risk were identified in PubMed, Embase, Web of Science, Cochrane Library and the Chinese Biomedical Medical Literature Database, through March 2012. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were calculated with a random-effects model. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.<h4>Results</h4>A total of 11 studies including 448,928 study subjects and 19,128 cancer patients were finally identified for the meta-analysis. Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence). Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence). Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer. Insulin glargine use was associated with lower odds of other site-specific cancer.<h4>Conclusions</h4>Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.Xulei TangLin YangZhiyu HeJingfang LiuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e51814 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xulei Tang Lin Yang Zhiyu He Jingfang Liu Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
description	<h4>Aim</h4>The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.<h4>Methods</h4>All observational studies and randomized controlled trials evaluating the relationship of insulin glargine and cancer risk were identified in PubMed, Embase, Web of Science, Cochrane Library and the Chinese Biomedical Medical Literature Database, through March 2012. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were calculated with a random-effects model. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.<h4>Results</h4>A total of 11 studies including 448,928 study subjects and 19,128 cancer patients were finally identified for the meta-analysis. Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence). Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence). Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer. Insulin glargine use was associated with lower odds of other site-specific cancer.<h4>Conclusions</h4>Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.
format	article
author	Xulei Tang Lin Yang Zhiyu He Jingfang Liu
author_facet	Xulei Tang Lin Yang Zhiyu He Jingfang Liu
author_sort	Xulei Tang
title	Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
title_short	Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
title_full	Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
title_fullStr	Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
title_full_unstemmed	Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
title_sort	insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/13714cf8c35a4c73948ef31ba6116386
work_keys_str_mv	AT xuleitang insulinglargineandcancerriskinpatientswithdiabetesametaanalysis AT linyang insulinglargineandcancerriskinpatientswithdiabetesametaanalysis AT zhiyuhe insulinglargineandcancerriskinpatientswithdiabetesametaanalysis AT jingfangliu insulinglargineandcancerriskinpatientswithdiabetesametaanalysis
_version_	1718422212314136576

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.

Ejemplares similares